Back to top

Company News For Jun 5, 2018

Read MoreHide Full Article
  • Genomic Health, Inc’s (GHDX - Free Report) shares jumped 23.1% after it disclosed that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefits of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25
  • Shares of Bayer Aktiengesellschaft BAYN.DE declined 0.5% after the company announced that it will retire the name of Monsanto after it finishes the $63 billion acquisition of the U.S. seed maker
  • Nektar Therapeutics’ (NKTR - Free Report) shared plummeted 41.8% after mixed results came in from studies combining Nektar’s experimental drug NKTR-214 with Bristol-Myers Squibb's cancer immunotherapy
  • Shares of Deciphera Pharmaceuticals, Inc. (DCPH - Free Report) rose 47.9% after the company at the ASCO Annual Meeting reported updated interim Phase 1 clinical study results with DCC-2618

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Genomic Health, Inc. (GHDX) - free report >>

Nektar Therapeutics (NKTR) - free report >>

Deciphera Pharmaceuticals, Inc. (DCPH) - free report >>

More from Zacks Corporate Summary

You May Like